JP2017014254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017014254A5 JP2017014254A5 JP2016159348A JP2016159348A JP2017014254A5 JP 2017014254 A5 JP2017014254 A5 JP 2017014254A5 JP 2016159348 A JP2016159348 A JP 2016159348A JP 2016159348 A JP2016159348 A JP 2016159348A JP 2017014254 A5 JP2017014254 A5 JP 2017014254A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- therapeutic agent
- agent according
- antagonistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 239000007787 solid Substances 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 12
- 230000001472 cytotoxic effect Effects 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 230000003042 antagnostic effect Effects 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 4
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 4
- 230000001270 agonistic effect Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000002257 antimetastatic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001483 mobilizing effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014032241 | 2014-02-21 | ||
| JP2014032241 | 2014-02-21 | ||
| JP2014120300 | 2014-06-11 | ||
| JP2014120300 | 2014-06-11 | ||
| JP2014178953 | 2014-09-03 | ||
| JP2014178953 | 2014-09-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016504046A Division JP6029160B2 (ja) | 2014-02-21 | 2015-02-09 | 固形がんの治療剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019025193A Division JP7041439B2 (ja) | 2014-02-21 | 2019-02-15 | 固形がんの治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017014254A JP2017014254A (ja) | 2017-01-19 |
| JP2017014254A5 true JP2017014254A5 (enExample) | 2018-03-22 |
| JP6578604B2 JP6578604B2 (ja) | 2019-09-25 |
Family
ID=53878157
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016504046A Active JP6029160B2 (ja) | 2014-02-21 | 2015-02-09 | 固形がんの治療剤 |
| JP2016159348A Active JP6578604B2 (ja) | 2014-02-21 | 2016-08-15 | 固形がんの治療剤 |
| JP2019025193A Active JP7041439B2 (ja) | 2014-02-21 | 2019-02-15 | 固形がんの治療剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016504046A Active JP6029160B2 (ja) | 2014-02-21 | 2015-02-09 | 固形がんの治療剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019025193A Active JP7041439B2 (ja) | 2014-02-21 | 2019-02-15 | 固形がんの治療剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20170165364A1 (enExample) |
| EP (3) | EP3338800A1 (enExample) |
| JP (3) | JP6029160B2 (enExample) |
| ES (1) | ES2808728T3 (enExample) |
| WO (1) | WO2015125652A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017062354A1 (en) * | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| EP4592391A3 (en) * | 2015-10-21 | 2025-10-08 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| KR20190019121A (ko) | 2016-06-17 | 2019-02-26 | 오사카 유니버시티 | 종양 내 정맥 형성 촉진제 |
| WO2018047917A1 (ja) * | 2016-09-09 | 2018-03-15 | 国立大学法人 東京大学 | Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果 |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| KR102843438B1 (ko) | 2017-06-02 | 2025-08-06 | 바이엘 헬쓰케어 엘엘씨 | 암을 치료하기 위한 레고라페닙 및 pd-1/pd-l1(2) 억제제의 조합 |
| TW201938580A (zh) * | 2018-03-08 | 2019-10-01 | 國立大學法人東京大學 | Ｈｍｇｎ部分肽及使用其之癌症療法 |
| GB201811291D0 (en) * | 2018-07-10 | 2018-08-29 | Univ Dublin City | A method of predicting response to treatment in cancer patients |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| EP4011918A4 (en) * | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
| US20240216401A1 (en) * | 2021-04-28 | 2024-07-04 | Obi Pharma, Inc. | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2027867A1 (en) * | 2000-10-20 | 2009-02-25 | Genetics Institute, LLC | Method and composition for inhibition of tumor growth and enhancing an immune response |
| JP2006523226A (ja) * | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | Ｔ細胞調節方法 |
| EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| CN109485727A (zh) * | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| CA2718184A1 (en) * | 2008-03-13 | 2009-10-08 | Biotest Ag | Agent for treating disease |
| CN102271711B (zh) * | 2008-12-12 | 2014-06-18 | 国立大学法人东京大学 | 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂 |
| EP2374883B1 (en) * | 2008-12-26 | 2016-08-10 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd4 antibody |
| IL300733B1 (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| CA3019531A1 (en) * | 2011-04-19 | 2012-10-26 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| CA2845536A1 (en) * | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2014189138A1 (ja) * | 2013-05-23 | 2014-11-27 | Ｉｄａｃセラノスティクス株式会社 | 免疫不全ウイルス感染の治療又は予防剤 |
| CN105979961B (zh) * | 2014-02-05 | 2020-12-18 | 西达-赛奈医疗中心 | 用于治疗癌症和感染性疾病的方法和组合物 |
| ES2818800T3 (es) * | 2014-06-11 | 2021-04-14 | Idac Theranostics Inc | Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario |
-
2015
- 2015-02-09 EP EP18153989.1A patent/EP3338800A1/en not_active Ceased
- 2015-02-09 JP JP2016504046A patent/JP6029160B2/ja active Active
- 2015-02-09 US US15/120,427 patent/US20170165364A1/en not_active Abandoned
- 2015-02-09 EP EP18153990.9A patent/EP3338801A1/en not_active Withdrawn
- 2015-02-09 ES ES15751324T patent/ES2808728T3/es active Active
- 2015-02-09 WO PCT/JP2015/053569 patent/WO2015125652A1/ja not_active Ceased
- 2015-02-09 EP EP15751324.3A patent/EP3132802B1/en active Active
-
2016
- 2016-08-15 JP JP2016159348A patent/JP6578604B2/ja active Active
-
2018
- 2018-12-27 US US16/234,292 patent/US20190125867A1/en not_active Abandoned
-
2019
- 2019-02-15 JP JP2019025193A patent/JP7041439B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017014254A5 (enExample) | ||
| JP2019070056A5 (enExample) | ||
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Morello et al. | Mesothelin-targeted CARs: driving T cells to solid tumors | |
| JP2019510733A5 (enExample) | ||
| Vela et al. | Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges | |
| JP2016537383A5 (enExample) | ||
| Guo et al. | Interleukin-6 signaling pathway in targeted therapy for cancer | |
| PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
| MX2025001300A (es) | Anticuerpos monoclonales anti-ctla4 humano quimericos y humanizados y sus usos | |
| JP2019503361A5 (enExample) | ||
| JP2016521692A5 (enExample) | ||
| JP2019513725A5 (enExample) | ||
| EP4464333A3 (en) | Anti-death receptor antibodies and methods of use thereof | |
| JP2016519651A5 (enExample) | ||
| HRP20180147T1 (hr) | Cea protutijela | |
| JP2017536340A5 (enExample) | ||
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| JP2019507183A5 (enExample) | ||
| WO2011159847A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof | |
| JP2017506264A5 (enExample) | ||
| WO2015109180A3 (en) | Compositions and methods for treatment and detection of cancers | |
| PE20180046A1 (es) | Anticuerpos terapeuticos y sus usos | |
| HRP20241357T1 (hr) | Optimizacija antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| MY208638A (en) | Anti-steap1 antigen-binding protein |